Financial Statements · From SEC 10-K & 10-Q XBRL Filings
Guardant Health Inc. Revenue & Financial Statements
Guardant Health Inc. reported revenue of $982.0M for the fiscal year ended December 31, 2025, up 32.9% year over year, with net income of $(416.3M) and diluted EPS of $-3.32.
- Company
- Guardant Health Inc. GH · NASDAQ
- Latest fiscal year
- FY ended Dec 31, 2025
- Statements
- Income · Balance Sheet · Cash Flow — 5 fiscal years, 8 quarters
Income Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 373.7M | 449.5M | 563.9M | 739.0M | 982.0M |
| Cost of revenue | — | — | — | — | 349.0M |
| Gross profit | — | — | — | — | 633.0M |
| Operating income | (411.0M) | (544.4M) | (564.7M) | (443.6M) | (437.2M) |
| Pretax income | 506K | 6.3M | 2.6M | 2.1M | (4.1M) |
| Net income | (413.1M) | (669.3M) | (463.6M) | (436.4M) | (416.3M) |
| Diluted EPS | -4.00 | -6.41 | -4.28 | -3.56 | -3.32 |
| EBITDA | (388.7M) | (508.4M) | (521.8M) | (401.2M) | (397.5M) |
Quarterly
| USD | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 168.5M | 177.2M | 191.5M | 201.8M | 203.5M | 232.1M | 265.2M | 281.3M |
| Cost of revenue | — | — | — | — | 74.7M | 81.2M | 93.6M | 99.5M |
| Gross profit | — | — | — | — | 128.7M | 150.9M | 171.6M | 181.8M |
| Operating income | (99.7M) | (100.6M) | (117.3M) | (126.0M) | (111.0M) | (106.4M) | (99.0M) | (120.8M) |
| Pretax income | (114.6M) | (102.5M) | (107.7M) | (110.3M) | (94.9M) | (99.9M) | (92.6M) | (130.2M) |
| Net income | (115.0M) | (102.6M) | (107.8M) | (111.0M) | (95.2M) | (99.0M) | (93.3M) | (128.5M) |
| Diluted EPS | -0.94 | -0.84 | -0.88 | -0.90 | -0.77 | -0.80 | -0.74 | -1.00 |
| EBITDA | (89.0M) | (90.5M) | (106.7M) | (115.5M) | (100.8M) | (96.8M) | (89.6M) | (110.8M) |
Balance Sheet
Fiscal year-end snapshots. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total assets | 2.2B | 1.6B | 1.8B | 1.5B | 2.0B |
| Current assets | 1.1B | 1.2B | 1.3B | 1.1B | 1.5B |
| Cash & equivalents | 492.2M | 141.6M | 1.1B | 525.5M | 378.2M |
| Total liabilities | 1.6B | 1.5B | 1.6B | 1.6B | 2.1B |
| Current liabilities | 194.7M | 193.2M | 205.9M | 225.6M | 302.7M |
| Long-term debt | — | — | — | — | 1.5B |
| Total debt | — | — | — | — | 1.5B |
| Stockholders’ equity | 645.0M | 60.2M | 158.7M | (139.6M) | (99.3M) |
| Net debt | — | — | — | — | 1.1B |
Cash Flow Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2022 | FY2023 | FY2024 | FY2025 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | (309.5M) | (325.0M) | (239.9M) | — | (184.8M) |
| Investing cash flow | 149.8M | 840.2M | (261.3M) | — | (627.2M) |
| Financing cash flow | (189.1M) | 477.4M | (996K) | — | 671.1M |
| Capital expenditure | 77.5M | 20.5M | 35.1M | — | 48.3M |
| Free cash flow | (386.9M) | (345.5M) | (274.9M) | — | (233.1M) |
| Dividends paid | — | — | — | — | — |
| Stock-based compensation | 94.7M | 90.8M | 140.4M | — | 166.2M |
Figures are parsed from SEC XBRL company facts and may be derived where issuers report year-to-date values (quarterly figures differenced; Q4 computed as FY minus Q3). Fiscal periods follow each company's fiscal calendar, not calendar years. Historical fact, not investment advice — verify with official SEC filings.
Every GH filing, connected
Financials beside price, insider trades, and 8-K events — with alerts the moment something new is filed.